Gufic Biosciences
BSE 509079
4 stories, newest first.
- USFDA Pre-Approval Inspection at Indore facility concludes with 3 observations
- Income Tax Appeal Allowed in Company's Favour; Rs. 4,33,36,680 Demand to Be Deleted
- Crisil Assigns Unsolicited ESG Rating of CRISIL ESG 62 (Strong) for FY 2025-26
- NSE Rejects Waiver; ₹1,72,000 Penalty to Be Paid by October 3, 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.